ライフサイエンスコーパス: type 2 diabetes mellitus

1 ts undergoing surgical procedures (4944 with type 2 diabetes mellitus).

2 ences encountered by patients suffering from type 2 Diabetes Mellitus.

3 which contributes to insulin resistance and type 2 diabetes mellitus.

4 n could be leveraged as a novel way to treat type 2 diabetes mellitus.

5 of IAPP and help explain its debated role in type 2 diabetes mellitus.

6 have potential in the control of obesity and Type 2 diabetes mellitus.

7 devastating complication of individuals with type 2 diabetes mellitus.

8 ue to or resulting in insulin resistance and type 2 diabetes mellitus.

9 and improves energy balance in patients with type 2 diabetes mellitus.

10 activators that could be useful for treating type 2 diabetes mellitus.

11 pancreatic beta cells and the development of type 2 diabetes mellitus.

12 nhibition by low-dose aspirin is impaired in type 2 diabetes mellitus.

13 n shown to be associated with overweight and type 2 diabetes mellitus.

14 ide to evaluate protein damage in nonsmoking type 2 diabetes mellitus.

15 atic beta cell function underlies type 1 and type 2 diabetes mellitus.

16 signed to improve the lives of patients with type 2 diabetes mellitus.

17 ptimal glycemic control in older adults with type 2 diabetes mellitus.

18 y is a promising avenue for the treatment of type 2 diabetes mellitus.

19 ic therapy for hypertension in patients with Type 2 diabetes mellitus.

20 ated metabolic disorders such as obesity and type 2 diabetes mellitus.

21 tality in patients with coronary disease and type 2 diabetes mellitus.

22 ished, effective agent for the management of type 2 diabetes mellitus.

23 therapy is feasible or improves outcomes in type 2 diabetes mellitus.

24 n thoracic aortic samples from patients with type 2 diabetes mellitus.

25 d beta-cell failure are the major defects in type 2 diabetes mellitus.

26 onditions such as coronary heart disease and type 2 diabetes mellitus.

27 e and are associated with increased risk for type 2 diabetes mellitus.

28 Statins increase the risk of new-onset type 2 diabetes mellitus.

29 , glucose intolerance and delay the onset of type 2 diabetes mellitus.

30 eventually contribute to the development of type 2 diabetes mellitus.

31 the contemporary management of patients with type 2 diabetes mellitus.

32 at have been widely used in the treatment of type 2 diabetes mellitus.

33 y study holds data for 8683 individuals with type 2 diabetes mellitus.

34 nstitute a novel target for the treatment of type 2 diabetes mellitus.

35 nd many other countries for the treatment of type 2 diabetes mellitus.

36 ergic receptor, ADRA2A--increase the risk of type 2 diabetes mellitus.

37 of macrovascular complications of type 1 and type 2 diabetes mellitus.

38 uctose consumption in people with type 1 and type 2 diabetes mellitus.

39 st promising strategies for the treatment of type 2 diabetes mellitus.

40 vascular and cardiovascular complications in type 2 diabetes mellitus.

41 ailure, chronic kidney disease, obesity, and type 2 diabetes mellitus.

42 ide a unique in vitro system emulating human type 2 diabetes mellitus.

43 Incident type 2 diabetes mellitus.

44 nefit of tighter BP control in patients with Type 2 diabetes mellitus.

45 ral adiposity have causal effects on CHD and type 2 diabetes mellitus.

46 eletion impairs insulin secretion and causes type 2 diabetes mellitus.

47 that uric acid has a role in the etiology of type 2 diabetes mellitus.

48 Insulin resistance is a risk factor for type 2 diabetes mellitus.

49 cal practice guideline for the management of type 2 diabetes mellitus.

50 r role in the development and progression of type 2 diabetes mellitus.

51 of 2 groups of morbidly obese patients with type 2 diabetes mellitus-1 managed by Roux-en-Y gastric

52 Prevalence of type 2 diabetes mellitus (15.5%-5.9%), hypertension (29.

53 Seven hundred and one individuals with type 2 diabetes mellitus (8%) developed heart failure du

54 The presence of type 2 diabetes mellitus, a defective allele mutation, e

55 o SGA use in youths, estimating the risk for type 2 diabetes mellitus, a rarer outcome, has been chal

56 of islet-amyloid polypeptide associated with type 2 diabetes mellitus, a-synuclein associated with Pa

57 knowledge of the molecular events underlying type 2 diabetes mellitus-a protein conformational diseas

58 A total of 105 subjects with type 2 diabetes mellitus (aged 54+/-10 years) and poor g

59 Insulin resistance or type 2 diabetes mellitus alters the systemic and neurohu

60 ion is a common comorbidity in patients with type 2 diabetes mellitus and a major risk factor for mic

61 tin Versus Standard of Care in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome]),

62 one of the most widely used therapeutics for type 2 diabetes mellitus and also has anticancer and ant

63 en adopted to combat complications caused by Type 2 diabetes mellitus and controlled diet is one of t

64 arction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular ris

65 rtality in Type 2 Diabetes) in patients with type 2 diabetes mellitus and established cardiovascular

66 lar morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular

67 nary bypass operations from 30 patients with type 2 diabetes mellitus and from 30 age- and sex-matche

68 ebo in patients with inadequately controlled type 2 diabetes mellitus and hypertension.

69 scular outcome trials in human subjects with type 2 diabetes mellitus and increased cardiovascular ri

70 tively associated with age, body mass index, type 2 diabetes mellitus and inversely with estimated gl

71 rglycemic drug that is widely prescribed for type 2 diabetes mellitus and is currently being investig

72 Remission rates of type 2 diabetes mellitus and metabolic syndrome and chan

73 ssions in arterial tissue from patients with type 2 diabetes mellitus and moreover hypothesized that

74 Moreover, insulin-resistant states such as type 2 diabetes mellitus and obesity increases the risk

75 anagement of hypertension, oxidative stress, type 2 diabetes mellitus and other aberrant cellular pro

76 olled, parallel group trial of subjects with type 2 diabetes mellitus and overt nephropathy receiving

77 ll detected in leukocytes from patients with type 2 diabetes mellitus and patients following cardiopu

78 6% of the Danish population have undiagnosed type 2 diabetes mellitus and prediabetes, respectively.

79 Patients with type 2 diabetes mellitus and prior cardiovascular events

80 HODS AND The study included 43 patients with type 2 diabetes mellitus and renal impairment (creatinin

81 ompared with hospital discharge diagnoses of type 2 diabetes mellitus and self-reported BMI.

82 dolescent metabolic syndrome (MetS) predicts type 2 diabetes mellitus and subclinical atherosclerosis

83 LP-1 agonist and is used in the treatment of type-2 diabetes mellitus and obesity.

84 ysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and

85 313 eligible SRs (86 for depression, 159 for type 2 diabetes mellitus, and 68 for chronic pain), few

86 ted States, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease.

87 bolic risk, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease.

88 chronic hypertension, hypercholesterolemia, type 2 diabetes mellitus, and changes in body mass index

89 ects by SRs on interventions for depression, type 2 diabetes mellitus, and chronic pain conditions (c

90 odels, patients had higher risks of obesity, type 2 diabetes mellitus, and circulatory system disease

91 8%-83%) of the variance in susceptibility to type 2 diabetes mellitus, and for 74% (95% CI, 72%-76%)

92 Primary outcomes were CHD, type 2 diabetes mellitus, and major stroke subtypes; sec

93 metformin, a first-line therapeutic drug for type 2 diabetes mellitus, and nelfinavir, an HIV proteas

94 Psoriasis, type 2 diabetes mellitus, and obesity are also strongly

95 sts of dyslipidemia, cardiovascular disease, type 2 diabetes mellitus, and obesity.

96 factors to the interaction between obesity, type 2 diabetes mellitus, and psoriasis.

97 oved as a new class of antidiabetic drugs in type 2 diabetes mellitus, and studies are under way to i

98 Patients with type 2 diabetes mellitus are at risk of heart failure.

99 Periodontitis and type 2 diabetes mellitus are known to be associated.

100 nd adipokine abnormalities (the hallmarks of type 2 diabetes mellitus) are characteristic features of

101 preclinical candidates for the treatment of type 2 diabetes mellitus, as well as a promising startin

102 hypertension, low diastolic blood pressure, type 2 diabetes mellitus (Asian population) increasing r

103 We ascertained cases of type 1 and type 2 diabetes mellitus at five study centers in the Un

104 EHR phenotypes related to type 2 diabetes mellitus, atherosclerotic, and hypertens

105 For type 2 diabetes mellitus, both measures had large effect

106 of cardiovascular events, breast cancer, and type 2 diabetes mellitus but may not affect all-cause mo

107 Secretion of this hormone is dysregulated in type 2 diabetes mellitus but the mechanisms controlling

108 smoking, hypertension, high cholesterol, and type 2 diabetes mellitus, but that the addition of CRF t

109 ms may improve outcomes for individuals with type 2 diabetes mellitus, but there is a large diversity

110 om trial data to the individual patient with type 2 diabetes mellitus by developing and validating a

111 otes glycemic reduction for the treatment of type 2 diabetes mellitus by glucose-dependent control of

112 in, high-density lipoprotein, triglycerides, type 2 diabetes mellitus, C-reactive protein, body mass

113 sity lipoprotein cholesterol, triglycerides, type 2 diabetes mellitus, C-reactive protein, body mass

114 in, high-density lipoprotein, triglycerides, type 2 diabetes mellitus, C-reactive protein, systolic b

115 e, hypercalcemia, weight gain, hypertension, type 2 diabetes mellitus, cardiovascular disease, and he

116 ronic kidney disease stage 4 or more severe, type 2 diabetes mellitus, cardiovascular disease, or hep

117 ing IL-18 concentrations are associated with type 2 diabetes mellitus, cardiovascular events, and div

118 litus incidence with an increasing number of type 2 diabetes mellitus cases being diagnosed in childr

119 ines for glycated hemoglobin A1c testing for type 2 diabetes mellitus could be improved to bring them

120 Screening for type 2 diabetes mellitus could lead to earlier identific

121 Using a murine model of type 2 diabetes mellitus (db/db mice), we identify progr

122 hether discrimination is related to incident type 2 diabetes mellitus (diabetes).

123 on of arterial basement membrane proteins in type 2 diabetes mellitus discloses a similarity between

124 ucose metabolism, but its role in preventing type 2 diabetes mellitus (DM) after gestational diabetes

125 s on HFD, the mice showed characteristics of type 2 diabetes mellitus (DM) and were mated with lean m

126 ociation between egg consumption and risk of type 2 diabetes mellitus (DM) have been inconsistent.

127 ness has rarely been examined in relation to type 2 diabetes mellitus (DM) in adulthood because of th

128 Type 2 diabetes mellitus (DM) is a risk factor for tuber

129 Although depression and type 2 diabetes mellitus (DM) may independently increase

130 assessed the first documented occurrence of type 2 diabetes mellitus (DM), chronic kidney disease (C

131 been suggested as a possible risk factor for type 2 diabetes mellitus (DM), results from existing epi

132 d changes in adult prevalence of obesity and type 2 diabetes mellitus (DM).

133 of the brain in Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2).

134 ividuals with chronic periodontitis (CP) and type 2 diabetes mellitus (DMt2) receiving scaling and ro

135 Patients with type 2 diabetes mellitus, established cardiovascular dis

136 flozin on clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular dis

137 educed mortality in vulnerable patients with type 2 diabetes mellitus, established cardiovascular dis

138 at baseline, of whom 67% had a diagnosis of type 2 diabetes mellitus for >10 years, 58% were receivi

139 m METASTROKE (12 389 ischemic stroke cases), type 2 diabetes mellitus from DIAGRAM (Diabetes Genetics

140 Data of 2725 patients with type 2 diabetes mellitus from the Lipid Lowering Arm of

141 For patients with type 2 diabetes mellitus, gaining neighborhood supermark

142 Patients with type 2 diabetes mellitus, glycohemoglobin between 6.5% a

143 increased risk of cardiovascular diseases in type 2 diabetes mellitus has been extensively documented

144 Hyperglycemia in type 2 diabetes mellitus has been linked to non-alcoholi

145 ntrol as primary prevention in patients with type 2 diabetes mellitus has changed substantially in th

146 use model, glipizide, a widely used drug for type 2 diabetes mellitus, has been identified to suppres

147 s index, waist circumference, triglycerides, type-2 diabetes mellitus, high-density lipoprotein and l

148 Weight, remission of type 2 diabetes mellitus, hypertension, dyslipidemia, de

149 ptomatic patients (age 58 +/- 12 years) with type 2 diabetes mellitus, hypertension, or obesity.

150 Incident type 2 diabetes mellitus identified through visit and ph

151 cable to a broad population of patients with type 2 diabetes mellitus in real-world practice.

152 te ratio = 2.83, 95% CI: 1.77, 4.53), as was type 2 diabetes mellitus (incidence rate ratio = 1.52, 9

153 were calculated for psoriasis in relation to type 2 diabetes mellitus, increasing BMI, and obesity in

154 Type 2 diabetes mellitus is a complex disease affecting

155 Type 2 diabetes mellitus is an independent risk factor f

156 Insulin-resistant type 2 diabetes mellitus is associated with reduced NO a

157 -deoxySLs also are elevated in patients with type 2 diabetes mellitus, L-serine supplementation could

158 Furthermore, in patients with type 2 diabetes mellitus, mortality is increased approxi

159 atric disorders (Crohn's disease, type 1 and type 2 diabetes mellitus, multiple sclerosis, or rheumat

160 e results were validated in a subcohort with type 2 diabetes mellitus (n=511) from the LIPID trial (L

161 umption of sugar is associated with obesity, type 2 diabetes mellitus, nonalcoholic fatty liver disea

162 sts are being developed for the treatment of type 2 diabetes mellitus, obesity, and nonalcoholic stea

163 on as well as to metabolic disorders such as type 2 diabetes mellitus, obesity, atherosclerosis and m

164 association was found between psoriasis and type 2 diabetes mellitus (odds ratio [OR], 1.53; 95% CI,

165 nfidence interval, 1.04-1.47; I(2)=68%), and type 2 diabetes mellitus (odds ratio, 1.37; 95% confiden

166 in a post hoc analysis in 1147 patients with type 2 diabetes mellitus on hemodialysis who participate

167 189) with atherosclerotic disease and either type 2 diabetes mellitus or impaired glucose tolerance w

168 In these patients with type 2 diabetes mellitus or impaired glucose tolerance,

169 m(2) (OR: 0.60), presence of IBS (OR: 6.29), type 2 diabetes mellitus (OR: 1.59) and gastritis (OR: 0

170 g cohorts of normoglycemic lean or obese and type 2 diabetes mellitus patients under good and poor gl

171 riod of August 2013 till July 2015 involving type 2 diabetes mellitus patients with no diabetic retin

172 lozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) demonstrated signific

173 flozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

174 elation was 0.80 when comparing EHR and ARIC type 2 diabetes mellitus phenotypes.

175 There was no significant association with type 2 diabetes mellitus (pooled RR: 0.97; 95% CI: 0.77,

176 agon-like peptide-1 analogs are approved for type 2 diabetes mellitus; preclinical and clinical data

177 cluding obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoho

178 f medications indicated for the treatment of type 2 diabetes mellitus, reduce inflammation and have b

179 Cardiovascular disease and type 2 diabetes mellitus represent overlapping diseases

180 rsus placebo) of 3878 and 2838 patients with type 2 diabetes mellitus, respectively.

181 HF as an important outcome in patients with type 2 diabetes mellitus seems to be heterogeneously mod

182 Among those with type 2 diabetes mellitus, significant sex differences oc

183 less tight glycemic control in patients with type 2 diabetes mellitus since the publication of UKPDS

184 and HF hospitalization risk in patients with type 2 diabetes mellitus (T2D) and cardiovascular diseas

185 Type 2 diabetes mellitus (T2D) arises from a dysregulate

186 Over the past decades, the prevalence of type 2 diabetes mellitus (T2D) has been steadily increas

187 Type 2 diabetes mellitus (T2D) is a major risk factor fo

188 d outlets, are hypothesized to contribute to type 2 diabetes mellitus (T2D).

189 entifying genes or processes of relevance to type 2 diabetes mellitus (T2D).

190 to insulin resistance and the development of type 2 diabetes mellitus (T2D).

191 ug signatures in the human gut microbiome of type 2 diabetes mellitus (T2D).

192 s well as heme iron intake, with the risk of type 2 diabetes mellitus (T2D).The Singapore Chinese Hea

193 l cells (BMSCs) derived from hyperglycaemic (type 2 diabetes mellitus, T2D) and normoglycaemic mice.

194 , an observational study on the remission of type 2 diabetes mellitus (T2DM) after different types of

195 ellitus (GDM) are at high risk of developing type 2 diabetes mellitus (T2DM) after pregnancy.

196 epression symptoms have been associated with type 2 diabetes mellitus (T2DM) among adults, little is

197 Despite the increasing prevalence of type 2 diabetes mellitus (T2DM) among children and adole

198 pped hyperglycemic clamp in 15 subjects with type 2 diabetes mellitus (T2DM) and 15 without diabetes

199 ion with obesity-related insulin resistance, type 2 diabetes mellitus (T2DM) and cardiovascular disea

200 Our studies in young murine models of type 2 diabetes mellitus (T2DM) and cardiovascular disea

201 eatment on serum biomarkers in patients with type 2 diabetes mellitus (t2DM) and chronic periodontiti

202 ning (SRP) in the treatment of patients with type 2 diabetes mellitus (T2DM) and chronic periodontiti

203 pleted in pancreatic islets in patients with type 2 diabetes mellitus (T2DM) and in db/db mice, an an

204 ntrol in patients who were being treated for type 2 diabetes mellitus (T2DM) and in patients who were

205 ronary microvascular dysfunction, is seen in type 2 diabetes mellitus (T2DM) and predicts cardiac mor

206 nflammation engenders insulin resistance and type 2 diabetes mellitus (T2DM) but the inflammatory eff

207 Type 2 diabetes mellitus (T2DM) damages the brain and fr

208 ividual CC lines were identified that showed type 2 diabetes mellitus (t2DM) development and signific

209 vulnerable to altered glucose metabolism in type 2 diabetes mellitus (T2DM) due to insulin resistanc

210 Metabolic profiling of individuals with type 2 diabetes mellitus (T2DM) has previously been limi

211 leotide polymorphisms (SNPs) associated with type 2 diabetes mellitus (T2DM) have been identified, bu

212 on between fruit consumption and the risk of type 2 diabetes mellitus (T2DM) have been inconsistent.W

213 n associated with reduced risk of developing type 2 diabetes mellitus (T2DM) however, the mechanism f

214 84 in ZPR1 has recently been associated with type 2 diabetes mellitus (T2DM) in Japanese individuals.

215 t increases in the prevalence of obesity and type 2 diabetes mellitus (T2DM) in modern societies have

216 Metabolic syndrome (MetS) and Type 2 diabetes mellitus (T2DM) increase risk for Alzhei

217 Type 2 diabetes mellitus (T2DM) is a common complication

218 Prevention of type 2 diabetes mellitus (T2DM) is a global priority.

219 Type 2 diabetes mellitus (T2DM) is a major risk factor f

220 logical findings support the hypothesis that type 2 diabetes mellitus (T2DM) is a risk factor for ost

221 Type 2 diabetes mellitus (T2DM) is a well-recognized ind

222 Although Type 2 diabetes mellitus (T2DM) is a well-recognized ris

223 Type 2 diabetes mellitus (T2DM) is a worldwide heath pro

224 Type 2 diabetes mellitus (T2DM) is associated with brain

225 Purpose Type 2 diabetes mellitus (T2DM) is becoming increasingly

226 of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a

227 Ketosis in patients with type 2 diabetes mellitus (T2DM) is overlooked due to aty

228 Type 2 diabetes mellitus (T2DM) may alter cardiac struct

229 ction and beta cell failure are hallmarks of type 2 diabetes mellitus (T2DM) pathogenesis.

230 In type 2 diabetes mellitus (T2DM) patients (n = 38), the l

231 in D supplementation on metabolic profile in Type 2 diabetes mellitus (T2DM) patients and this might

232 However, endurance trained athletes and type 2 diabetes mellitus (T2DM) patients store similar a

233 ting and functional phenotyping strategy for type 2 diabetes mellitus (T2DM) patients using small blo

234 Compared to type 2 diabetes mellitus (T2DM) patients, Trained subjec

235 Type 2 diabetes mellitus (T2DM) represents a rapidly inc

236 ic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically

237 ed coexistence of Alzheimer disease (AD) and type 2 diabetes mellitus (T2DM) suggests that insulin re

238 PPARgamma is the molecular target for type 2 diabetes mellitus (T2DM) therapeutics TZDs (thiaz

239 protein 3 (IGFBP-3) might raise the risk of type 2 diabetes mellitus (T2DM) via binding of insulin-l

240 ars and older to evaluate the association of type 2 diabetes mellitus (T2DM) with the risk of sarcope

241 le of red blood cells (RBC) deformability in type 2 diabetes mellitus (T2DM) without and with diabeti

242 nic periodontitis (CP), patients with CP and type 2 diabetes mellitus (T2DM), and healthy individuals

243 athy (DR) among Chinese American adults with type 2 diabetes mellitus (T2DM), and to compare these fa

244 advance in the pharmacological management of type 2 diabetes mellitus (T2DM), as these agents avoid h

245 serum urate levels are causally relevant in type 2 diabetes mellitus (T2DM), coronary heart disease

246 ionally, coffee is inversely associated with type 2 diabetes mellitus (T2DM), depression and Alzheime

247 (s) of K cells for the incretin response and type 2 diabetes mellitus (T2DM), diphtheria toxin-expres

248 ion, BMP-9 was independently associated with type 2 diabetes mellitus (T2DM), HOMA-IR and FFA.

249 y mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, m

250 In a mouse model of type 2 diabetes mellitus (T2DM), long-term treatment wit

251 ition from normal glucose tolerance (NGT) to type 2 diabetes mellitus (T2DM), the role of beta-cell d

252 ntribute to diabetic polyneuropathy (DPN) in type 2 diabetes mellitus (T2DM), we treated the BKS db/d

253 The prevalence of early-onset type 2 diabetes mellitus (T2DM), which responds poorly t

254 omising drug candidates for the treatment of Type 2 diabetes mellitus (T2DM).

255 gs, are important new classes of therapy for type 2 diabetes mellitus (T2DM).

256 .7 mmol/L) has been strongly associated with type 2 diabetes mellitus (T2DM).

257 (HF) is a common and serious complication in type 2 diabetes mellitus (T2DM).

258 and is frequently observed in patients with type 2 diabetes mellitus (T2DM).

259 se might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM).

260 viral therapy (ART) may increase the risk of type 2 diabetes mellitus (T2DM).

261 tive methods to assess this in patients with type 2 diabetes mellitus (T2DM).

262 ance leads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM).

263 chronic periodontitis (CP) in patients with type 2 diabetes mellitus (t2DM).

264 nts but increase the risk for a diagnosis of type 2 diabetes mellitus (T2DM).

265 inflammatory conditions among patients with type 2 diabetes mellitus (T2DM).

266 a key player in metabolic disorders, such as Type 2 Diabetes Mellitus (T2DM).

267 role and durability of bariatric surgery for type 2 diabetes mellitus (T2DM).

268 een associated with a high remission rate of type 2 diabetes mellitus (T2DM).

269 onists have emerged as treatment options for type 2 diabetes mellitus (T2DM).

270 ular and heart failure risk in patients with type 2 diabetes mellitus (T2DM).

271 thought to play a role in the development of type 2 diabetes mellitus (T2DM).

272 mortality in trials of intensive therapy in type 2 diabetes mellitus (T2DM).

273 per cent of all the diabetic population has type 2 diabetes mellitus (T2DM).

274 eptide (IAPP), a critical pathogenic step in type 2 diabetes mellitus (T2DM).

275 nt candidate drug target in the treatment of type 2 diabetes mellitus (T2DM).

276 as been proposed as an approach for treating type 2 diabetes mellitus (T2DM).

277 mpact on adult metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM).The longitudinal cohort

278 chronic periodontitis (CP) with and without type 2 diabetes mellitus (t2DM); 2) analyze the relation

279 Erythrocytes in patients with type-2 diabetes mellitus (T2DM) are associated with redu

280 ) randomly assigned 10 142 participants with type 2 diabetes mellitus to canagliflozin or placebo.

281 11 proteins were identified in patients with type 2 diabetes mellitus under poor glycemic control.

282 Of the 173 obese patients with type 2 diabetes mellitus undergoing gastric bypass surge

283 A cohort of obese patients with and without type 2 diabetes mellitus undergoing vertical sleeve gast

284 ately estimated for individual patients with type 2 diabetes mellitus using a model based on routinel

285 ironmental correlation between psoriasis and type 2 diabetes mellitus was 0.10 (-0.71 to 0.17; P = .6

286 he genetic correlation between psoriasis and type 2 diabetes mellitus was 0.13 (-0.06 to 0.31; P = .1

287 tion, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than

288 ength and stroke, myocardial infarction, and type 2 diabetes mellitus were independently selected for

289 A total of 27 obese patients with type 2 diabetes mellitus were randomized to Roux-en-Y ga

290 s a key role in control of hypertension, and type-2 diabetes mellitus, which frequently co-exist.

291 Clinical Question: Among patients with type 2 diabetes mellitus who do not achieve optimal glyc

292 tor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardio

293 ular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic

294 quid meal test in 20 obese participants with type 2 diabetes mellitus who underwent RYGB or nonsurgic

295 All participants had type 2 diabetes mellitus with >/=1 additional cardiovasc

296 ation-based cohort study among patients with type 2 diabetes mellitus with established cardiovascular

297 ease, spanning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk

298 ion arm in overweight/obese individuals with type 2 diabetes mellitus with triglyceride (n=3214) and

299 art failure (HF) is increased in people with type 2 diabetes mellitus, with risk directly associated

300 ed a substantial proportion of patients with type 2 diabetes mellitus without clinically recognized e